Abstract
Coronavirus disease 19 (COVID-19) is a global health crisis on a planetary scale. COVID-19 in many people has mild or moderate manifestation, although significant number of people, especially the elderly, suffer heavy from this illness, which often resulting in death. There are reports of similarities in immune response between COVID-19 and some autoimmune diseases. Earlier, we have demonstrated that fraction of TCA-soluble blood serum proteins containing a 48 kDA fragment of unconvential Myosin C1 have linked with development of multiple sclerosis and rheumatoid arthritis. Here we analyze use of these proteins in determining the severity of disease in COVID-19 patients. We found that blood serum of COVID-19 patients in acute disease manifestation contains, in contrast to healthy individuals, the TCA-soluble proteins with molecular masses 48 kDa and 76 kDA which were identified as a short form of unconventional myosin 1c and a modified form of human serum albumin.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Сommission of bioethical examination of Institute of Cell Biology, National Academy of Sciences of Ukraine Head of Commission, Oleh Stasyk, Ph.D Head of Department of Cell Signaling Members of the commission: Rostyslav Stoika, Ph.D, Professor Head of Department of Regulation of Cell Proliferation and Apoptosis Maxym Lutsyk, Ph.D, MD,Professor Leading Researcher of Department of Regulation of Cell Proliferation and Apoptosis Yaroslav Bobak Ph.D. Senior Researcher of Department of Cell Signaling
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Abbreviation
- TCA
- 2,2,2-trichloroacetic acid
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos